Consumer Reports warns that there are important considerations, especially for older adults, before starting these treatments ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

combining semaglutide — the active ingredient in Wegovy — with amylin analog Cagrilintide, a nascent form of weight loss treatment. However, positive early-stage results for its once weekly ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Sales of the company's blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year. Sales of Wegovy surged to 19.87 billion ...

Novo Nordisk's blockbuster Wegovy weight-loss drug just missed sales expectations in the fourth quarter despite more than doubling on the year. The Danish pharmaceutical giant said sales of Wegovy ...